Login
Navigate Fool.com
Will VRX beat
the market?
Community Rating: 3 Stars: Appealing

134.42 1.19 (0.89%)

REAL-TIME: Last trade at

company name or ticker

Recent Quotes

1D 1W 3M 6M 1Y 2Y 3Y
Today's Open $133.13
Previous Close $133.23
Daily Range $130.57 - $135.52
52-Week Range $71.99 - $153.10
Market Cap $45.0B
P/E Ratio -49.34
Dividend (Yield) $0.00 (0.0%)
Volume 3,109,829
Average Daily Volume 2,959,626
Current FY EPS $2.96

How do you think VRX
will perform against the market?

Top VRX Bull/Bear Pitches

 

crimfunk (< 20)
Submitted February 2, 2008

undervalued, EPS 5 Year Growth (%) 199.82

0 Replies Reply Report this Post
 

tenmiles (< 20)
Submitted August 22, 2008

Technically ripe for 10-15% retracement from current $20.32 level; fundies aren't so hot either - seller here

0 Replies Reply Report this Post

News & Commentary Rss Feed

Inside Valeant Pharmaceuticals' Bid for Allergan

Here’s why this pharmaceutical megamerger seems like a good deal for both companies.

Can Allergan Find an Alternative To Valeant?

Valeant has made a bold bid for Allergan, but Allergan does not appear too happy to see it.

Allergan, Inc.: Another Billion-Dollar Buyout Target

Valeant might continue its acquisition streak with the hefty purchase of Allergan.

Why Valeant International Inc. Is Acquiring Botox and Juvederm Maker Allergan

Valeant's proposed acquisition of Allergan would create a virtual lock on the cosmetic injectables market, bringing several of the top competitors into one portfolio.

Wednesday's Artery-Clogging Fast-Food Earnings Reports, and Potential Botox Merger

Good morning, good lookin'... The 3 things you need to know on April 23rd are:

Why GW Pharmaceuticals, Revance Therapeutics, and Allergan Are Today's 3 Best Stocks

M&A activity sends the S&P 500 decisively higher as GW Pharmaceuticals, Revance Therapeutics, and Allergan all jump by double digits.

Why Allergan Inc. Shares Skyrocketed

Allergan shares soared after receiving an unsolicited takeover bid from a rival. See how much of a premium Allergan shareholders are being offered and what they should do in response to this offer.

Midday Update: Stocks Grind Higher Thanks to Earnings, Economic Data and M&A Activity

Allergan: Here's Why Ackman and Valeant Want the Botox Maker

Here's what you need to know about Valeant's (VRX) planned $45 billion acquisition of Allergan (AGN),

Today's Health-Care Stocks to Watch: Allergan, Inc., AstraZeneca, Pfizer, and Valeant Pharmaceutical

Today's top stories in health care and biotech.

See More VRX News...

Sector

Healthcare

Industry

Drugs

Valeant Pharmaceuticals (VRX) Description

A global specialty pharmaceutical company that develops, manufactures and markets a range of pharmaceutical products, primarily in the areas of neurology, infectious disease, and dermatology. Website: http://www.valeant.com/

Featured Broker Partners

Learn more about our new Fool ticker page!

Take a Tour
no thanks